[go: up one dir, main page]

DE69738754D1 - Hemmer der interaktion zwischen p53 und mdm2 - Google Patents

Hemmer der interaktion zwischen p53 und mdm2

Info

Publication number
DE69738754D1
DE69738754D1 DE69738754T DE69738754T DE69738754D1 DE 69738754 D1 DE69738754 D1 DE 69738754D1 DE 69738754 T DE69738754 T DE 69738754T DE 69738754 T DE69738754 T DE 69738754T DE 69738754 D1 DE69738754 D1 DE 69738754D1
Authority
DE
Germany
Prior art keywords
compounds
mdm2
interaction
human
hemmer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69738754T
Other languages
English (en)
Inventor
David Lane
Volker Boettger
Angelika Boettger
Stephen Picksley
Heinz-Kurt Hochkeppel
Carlos Garcia-Echeverria
Patrick Chene
Pascal Furet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614197.3A external-priority patent/GB9614197D0/en
Priority claimed from GBGB9707041.1A external-priority patent/GB9707041D0/en
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Application granted granted Critical
Publication of DE69738754D1 publication Critical patent/DE69738754D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Amplifiers (AREA)
DE69738754T 1996-07-05 1997-07-04 Hemmer der interaktion zwischen p53 und mdm2 Expired - Fee Related DE69738754D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9614197.3A GB9614197D0 (de) 1996-07-05 1996-07-05
GBGB9707041.1A GB9707041D0 (en) 1997-04-07 1997-04-07 Inhibitors of the interaction between p53 and mdm2
PCT/EP1997/003549 WO1998001467A2 (en) 1996-07-05 1997-07-04 Inhibitors of the interaction between p53 and mdm2

Publications (1)

Publication Number Publication Date
DE69738754D1 true DE69738754D1 (de) 2008-07-17

Family

ID=26309649

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738754T Expired - Fee Related DE69738754D1 (de) 1996-07-05 1997-07-04 Hemmer der interaktion zwischen p53 und mdm2

Country Status (8)

Country Link
EP (1) EP0958305B1 (de)
JP (1) JP2001500365A (de)
AT (1) ATE397621T1 (de)
AU (1) AU3847997A (de)
CA (1) CA2259149A1 (de)
DE (1) DE69738754D1 (de)
NZ (1) NZ333609A (de)
WO (1) WO1998001467A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
EP0989136A4 (de) * 1997-05-15 2002-10-09 Kyowa Hakko Kogyo Kk Peptide mit zyklischen strukturen, die die aktivität von mutierten p53 proteinen wiederherstellen können.
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
EP0947494A1 (de) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Phenoxyessigsäure- und Phenoxymethyltetrazolderivate mit Antitumoraktivität
ATE283915T1 (de) * 1998-05-26 2004-12-15 Inst Of Molecul & Cell Biology Polypeptide aus dem creb-bindenden protein und verwandten protein p-300 zur verwendung bei der transkriptionellen regulation
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
US7192713B1 (en) * 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20040038902A1 (en) 2000-04-05 2004-02-26 Pincus Matthew R. Peptides selectively lethal to malignant and transformed mammalian cells
WO2004073615A2 (en) 2003-02-13 2004-09-02 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Deazaflavin compounds and methods of use thereof
DK2332968T3 (en) 2003-11-05 2016-08-22 Dana Farber Cancer Inst Inc Alpha-helix peptides suitable for activating or inhibiting cell death
WO2005097820A1 (en) * 2004-04-06 2005-10-20 Korea Research Institute Of Bioscience And Biotechnology Peptides for inhibiting mdm2 function
CN1957094A (zh) * 2004-04-22 2007-05-02 奥索-麦克尼尔药品公司 Hdm2－抑制剂复合物及其用途
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2142562B1 (de) 2007-03-28 2013-07-03 President and Fellows of Harvard College Geheftete polypeptide
CN102256615A (zh) 2009-01-14 2011-11-23 爱勒让治疗公司 拟肽大环化合物
CA2765657A1 (en) * 2009-06-16 2010-12-23 Tokai University Anti-gram-negative bacteria agent
WO2011005219A1 (en) * 2009-07-07 2011-01-13 Agency For Science, Technology And Research Novel mdm2 binding peptides and uses thereof
BR112012008075A2 (pt) 2009-08-26 2016-03-01 Novartis Ag compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN108570097A (zh) 2010-08-13 2018-09-25 爱勒让治疗公司 拟肽大环化合物
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (de) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl-isochinolinon-verbindungen
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
JP6162135B2 (ja) * 2011-11-09 2017-07-12 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 短縮された生物活性を示す神経毒
US9408885B2 (en) * 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2819688A4 (de) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazol- und thioethervernetzte peptidomimetische makrozyklen
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP2948451B1 (de) 2013-01-22 2017-07-12 Novartis AG Substituierte purinonverbindungen
EP3412675A1 (de) 2013-05-27 2018-12-12 Novartis AG Imidazopyrrolidinonderivate und deren verwendung bei der behandlung einer krankheit
ES2650562T3 (es) 2013-05-28 2018-01-19 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades
EP3004108B1 (de) 2013-05-28 2017-10-18 Novartis AG Pyrazolo-pyrrolidin-4-on-derivate als bet inhibitoren und ihre verwendung bei der behandlung von krankheiten
EA029269B1 (ru) 2013-11-21 2018-02-28 Новартис Аг Производные пирролопирролона и их применение для лечения заболеваний
MX2017003797A (es) * 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
JP2021506814A (ja) 2017-12-15 2021-02-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化ペプチドによって介在される標的タンパク質の分解
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN109206474A (zh) * 2018-11-27 2019-01-15 青岛海洋生物医药研究院 一种线性肽合成方法
CN113677357A (zh) * 2019-02-20 2021-11-19 昂科莱奇公司 用于治疗癌症的hdm2抗体
CN112266407B (zh) * 2020-09-28 2023-05-12 宁夏医科大学总医院 特异结合p53蛋白的七肽、编码基因、制备方法及用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Also Published As

Publication number Publication date
EP0958305B1 (de) 2008-06-04
ATE397621T1 (de) 2008-06-15
EP0958305A2 (de) 1999-11-24
AU3847997A (en) 1998-02-02
NZ333609A (en) 2000-08-25
WO1998001467A2 (en) 1998-01-15
JP2001500365A (ja) 2001-01-16
CA2259149A1 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69937294D1 (de) Von cyclophilin b abstammende tumorantigen-peptide
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
AU3804500A (en) 2-amino-6-anilino-purines and their use as medicaments
IL115517A0 (en) Biologically active proteins
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
PT848720E (pt) Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
ATE230263T1 (de) At1 rezeptor antagonist zur anregung von apoptosis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee